


In the claims:

1. (Currently Amended) A compound of formula (I):



(I)

wherein:

R¹ is H, CH₂R⁵ or COR⁶;

R² is alkyl C₁₋₆ or alkenyl C₁₋₆, optionally substituted by one or more groups selected from alkyl C₁₋₆ and halogen;

R³ is cycloalkyl C₃₋₈, optionally substituted by R⁷;

R⁴ is H or alkyl C₁₋₆, optionally substituted by one or more halogens;

R⁵ is H, phenyl or alkyl C₁₋₆, optionally substituted by halogen, OR⁸, and phenyl;


R⁶ is OR⁹ or alkyl C₁₋₆, optionally substituted by one or more groups selected from halogen, OR¹⁰, and phenyl;

R⁷ is phenyl, optionally substituted by one or more groups selected from alkyl C₁₋₆, halogen, and OR⁸;

R⁸, R⁹ and R¹⁰, are independently H or alkyl C₁₋₆, optionally substituted by one or more groups selected from halogen or alkyl C₁₋₆;

or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt.

2. (Previously Presented) A compound of according to claim 1 which is:



(Ia)

where R^1 , R^2 , R^3 and R^4 are as defined in claim 1.

3. (Currently Amended) A compound according to claim 1 or 2 in which R^3 is



wherein:

R^7 is phenyl, optionally substituted by one or more groups selected from alkyl C_{1-6} , halogen, and OR^8 .

R^8 is independently H or alkyl C_{1-6} , optionally substituted by one or more groups selected from halogen or alkyl C_{1-6} .

where R^7 is as defined in claim 1.

4. (Currently Amended) A compound according to ~~any one of~~ claims 1 or 2 ~~to 3~~ in which R^1 is H, CH_2Ph , CH_2CH_2OH , or CO_2tBu .

5. (Currently Amended) A compound according to ~~any one of~~ claims 1 or 2 ~~to 4~~ in which R^2 is n-Pr.

6. (Currently Amended) A compound according to ~~any one of~~ claims 1 or 2 ~~to 5~~ in which R³ is cycloalkyl C₃₋₈ substituted by phenyl.

7. (Currently Amended) A compound according to ~~any one of~~ claims 1 or 2 ~~to 6~~ in which R⁴ is H or methyl.

8. (Currently Amended) A compound according to claim 1 which is:

[3*R*-[3 α ,4 β (1*R**,2*S**)]]-4-[7-[(2-Phenylcyclopropyl)amino]-5-(propylthio)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-3-pyrrolidinol;

[3*S*-[3 α ,4 β (1*S**,2*R**)]]-3-Hydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-1-pyrrolidinecarboxylate, 1,1-dimethylethyl ester;

[3*S*-[3 α ,4 β (1*R**, 2*S**)]]-3-Hydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-1-pyrrolidinecarboxylate, 1,1-dimethylethyl ester;

[3*S*-[3 α ,4 β (1*S**,2*R**)]]-4-[7-[(2-Phenylcyclopropyl)amino]-5-(propylthio)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-3-pyrrolidinol;

[3*R*-[3 α ,4 β (1*R**,2*S**)]]-4-[7-[*N*-Methyl-*N*-(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-3-pyrrolidinol;

[3*R*-[3 α ,4 β (1*R**,2*S**)]]-1-Hydroxyethyl-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-3-pyrrolidinol;

[3*R*-[3 α ,4 β (1*R**,2*S**)]]-4-[7-[(2-Phenylcyclopropyl)amino]-5-(propylthio)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-1-(phenylmethyl)-3-pyrrolidinol;

[3*R*-[3 α , 4 β (1*R**,2*S**)]]-1-Acetyl-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-3-pyrrolidinol;

or ~~Or~~ a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt.

9. **(Currently Amended)** A pharmaceutical composition comprising a compound according to ~~any one of~~ claims 1 or 2 ~~to 8~~ in combination with a pharmaceutically acceptable diluent, ~~adjuvant~~ adjuvant or carrier.


10-16. **(Cancelled)**

17. **(Currently Amended)** A method of treatment ~~or prevention~~ of a platelet aggregation disorder which comprises administering to a person suffering from or susceptible to such a disorder a therapeutically effective amount of compound according to ~~any one of~~ claims 1 or 2 ~~to~~ 8.

18. **(Currently Amended)** A method of treatment ~~or prevention~~ of myocardial infarction, thrombotic stroke, transient ischaemic attacks, and/or peripheral vascular disease, which comprises administering to a person suffering from or susceptible to such a disorder a therapeutically effective amount of a compound according to ~~any one of~~ claims 1 or 2 ~~to 8~~.

19. **(Currently Amended)** A method of treatment ~~or prevention~~ of unstable or stable angina, which comprises administering to a person suffering from or susceptible to such a disorder a therapeutically effective amount of a compound according to ~~any one of~~ claims 1 or 2 ~~to 8~~.

20. **(Previously Presented)** A process for the preparation of a compound of formula (I), where R^1 is H, which comprises reacting a compound of formula (II)



(II)

wherein R^2 is as defined in claim 1 and P is a protecting group, with R^3R^4NH , wherein R^3 and R^4 are as defined in claim 1, and a base and optionally thereafter removing any protecting groups.

21. **(Cancelled)**